A potential FDA approval of the sNDA will expand the indication for Nubeqa in patients with mHSPC to include Nubeqa both with and without chemotherapy. BAYRY is also evaluating darolutamide across ...

“If approved, this would expand the indication ... "Bayer expands indications for Nubeqa with new drug application" was originally created and published by Clinical Trials Arena, a GlobalData ...

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 ...

The drug was approved by the FDA in July last year ... The trial showed that Nubeqa plus androgen deprivation therapy (ADT) demonstrated a highly significant improvement in the primary efficacy ...